Endocrinology News

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.

Early postmenopausal women who receive zoledronate every 5 years have a lower risk for morphometric vertebral fractures than those receiving placebo, according to trial findings published in The New England Journal of Medicine.

A new error grid to assess the accuracy of glucose measurements could give continuous glucose monitor manufacturers and regulatory agencies such as the FDA a better understanding of how accurate their devices are.

New data suggest Restylane Lyft or Contour in combination with Sculptra corrects contour deficiencies in patients experiencing facial volume loss following medication-driven weight loss, according to a Galderma press release.

Aerobic exercise has been linked to reductions in several measures of body fat, including body weight and waist circumference, a systematic review and meta-analysis in JAMA Network Open found.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

Use of SGLT2 inhibitors was associated with improved kidney health among a diverse multiethnic cohort of Asian adults with type 2 diabetes, researchers found in a retrospective cohort study.

Men were less likely than women to have weight-loss surgery, and that gap has widened over time, while Black patients were less likely than those of other races to have a procedure, and that gap has narrowed slightly, new data show.

High genetically predicted LDL was inversely associated with risk for incident diabetes, whereas the opposite trend was observed for CAD risk, researchers reported.